Inhibition OF USP7 Induces Selective Cancer Cell Death in Chronic Lymphocytic Leukemia

CLL is a lymphoproliferative disorder with indolent clinical course. Beside standard chemoimmunotherapy, higher risk subgroups -namely those harboring TP53 mutations or deletions of the short arm of chromosome 17 (del17p)- may benefit from newer targeted drugs which act downstream of the B cell receptor.

Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Giovanna Carr à, Cristina Panuzzo, Davide Torti, Guido Parvis, Sabrina Crivellaro, Marco Volante, Deborah Morena, Marcello Lingua, Mara Brancaccio, Angelo Guerrasio, Pier Paolo Pandolfi, Giuseppe Saglio, Riccardo Taulli, Alessandro Morotti Source Type: research